Next Article in Journal
Vaccine Hesitancy in China: A Qualitative Study of Stakeholders’ Perspectives
Next Article in Special Issue
SARS-CoV-2 Proteins Induce IFNG in Th1 Lymphocytes Generated from CD4+ Cells from Healthy, Unexposed Polish Donors
Previous Article in Journal
Generation and Characterization of Universal Live-Attenuated Influenza Vaccine Candidates Containing Multiple M2e Epitopes
Previous Article in Special Issue
The Strange Case of BCG and COVID-19: The Verdict Is Still up in the Air
Review

COVID-19 Vaccines Currently under Preclinical and Clinical Studies, and Associated Antiviral Immune Response

by 1,†, 1,†, 2,† and 3,*
1
Department of Biology, The Catholic University of America, Washington, DC 20064, USA
2
CHI Health, Department of Pulmonary Medicine, Creighton University Medical Center, Omaha, NE 68131, USA
3
Department of Anesthesiology, University of Nebraska Medical Center, Omaha, NE 68198, USA
*
Author to whom correspondence should be addressed.
These authors contributed equally.
Vaccines 2020, 8(4), 649; https://doi.org/10.3390/vaccines8040649
Received: 24 September 2020 / Revised: 17 October 2020 / Accepted: 29 October 2020 / Published: 3 November 2020
With a death toll of over one million worldwide, the COVID-19 pandemic caused by SARS-CoV-2 has become the most devastating humanitarian catastrophe in recent decades. The fear of acquiring infection and spreading to vulnerable people has severely impacted society’s socio-economic status. To put an end to this growing number of infections and deaths as well as to switch from restricted to everyday living, an effective vaccine is desperately needed. As a result, enormous efforts have been made globally to develop numerous vaccine candidates in a matter of months. Currently, over 30 vaccine candidates are under assessment in clinical trials, with several undergoing preclinical studies. Here, we reviewed the major vaccine candidates based on the specific vaccine platform utilized to develop them. We also discussed the immune responses generated by these candidates in humans and preclinical models to determine vaccine safety, immunogenicity, and efficacy. Finally, immune responses induced in recovered COVID-19 patients and their possible vaccine development implications were also briefly reviewed. View Full-Text
Keywords: COVID-19; SARS-CoV-2; vaccine development; vaccine platforms; vaccine response; neutralizing antibodies; T-cell responses; convalescent patients COVID-19; SARS-CoV-2; vaccine development; vaccine platforms; vaccine response; neutralizing antibodies; T-cell responses; convalescent patients
Show Figures

Figure 1

MDPI and ACS Style

Jain, S.; Batra, H.; Yadav, P.; Chand, S. COVID-19 Vaccines Currently under Preclinical and Clinical Studies, and Associated Antiviral Immune Response. Vaccines 2020, 8, 649. https://doi.org/10.3390/vaccines8040649

AMA Style

Jain S, Batra H, Yadav P, Chand S. COVID-19 Vaccines Currently under Preclinical and Clinical Studies, and Associated Antiviral Immune Response. Vaccines. 2020; 8(4):649. https://doi.org/10.3390/vaccines8040649

Chicago/Turabian Style

Jain, Swati, Himanshu Batra, Poonam Yadav, and Subhash Chand. 2020. "COVID-19 Vaccines Currently under Preclinical and Clinical Studies, and Associated Antiviral Immune Response" Vaccines 8, no. 4: 649. https://doi.org/10.3390/vaccines8040649

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop